Stockscreener 앱 받기
4.19
2.95%
0.12
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - The Manila Times
Europe authorizes first drug for patients with relentless hunger - Stock Titan
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
MSN Money - MSN
X4 Pharmaceuticals (XFOR) Stock: Directional Bias Review | Q4 2025: Earnings Beat EstimatesCrowd Trend Signals - Newser
$1.9B deal gives Chiesi first oral, on-demand hereditary angioedema treatment - Stock Titan
X4 Pharmaceuticals gets EU approval for WHIM syndrome drug By Investing.com - Investing.com Canada
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - The Manila Times
A rare immune disorder gets its first approved treatment across Europe - Stock Titan
Layoff Tracker: Novartis cuts hit New Jersey again, affecting 60 employees - BioSpace
China SXT Pharmaceuticals (SXTC) Co-CEO reports indirect Class B stake - Stock Titan
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date - The Economic Times
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
ROKU (Roku Inc.) tops Q4 2025 EPS estimates by a wide margin, shares rise nearly 4 percent in today’s session.Trending Stock Ideas - Xã Thanh Hà
Is X4 Pharmaceuticals (XFOR) stock a solid choice for investors | Q4 2025: Earnings Beat Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma (LQDA) - Seeking Alpha
Tax-driven RSU share sale by KalVista (KALV) CCO Nicole Sweeny - Stock Titan
Tax-related share sale by KalVista (KALV) CEO after RSU vesting - Stock Titan
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - TradingView
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results - GlobeNewswire
X4 Pharmaceuticals (XFOR) Stock: Next Quarter (Institutional Demand) 2026-04-18Crowd Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis (NASDAQ: IONS) director sells 5,000 shares under Rule 10b5-1 plan - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Insider Sell: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Breakouts & Breakdowns & Weekly High Potential Alerts - baoquankhu1.vn
EPS Watch: How does X4 Pharmaceuticals Inc score in quality rankings2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Setups: What is the long term forecast for X4 Pharmaceuticals Inc stock - baoquankhu1.vn
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - TradingView — Track All Markets
Setup Watch: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Leading Companies Reinforcing Their Presence in the C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - openPR.com
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year - Yahoo Finance
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Weekly Trades: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PR Newswire
Meme Stocks: Is X4 Pharmaceuticals Inc a momentum stock2026 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Recursion (NASDAQ: RXRX) director sale under Rule 10b5-1 trading plan - Stock Titan
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for - GlobeNewswire
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Aug Selloffs: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times
XFOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
XFOR Stock Analysis: X4 Pharmaceuticals Inc. gains 5.33 percent to trade at 4.35 - Newser
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Icahn-affiliated entities reshape Viskase Holdings (ENZN) stake in merger - Stock Titan
Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire
2.45%
자본화:
|
볼륨(24시간):